Peer-Reviewed Published Study Provides Further Evidence for the Safety and Efficacy of Nerivio® in Patients with Chronic Migraine

NETANYA, Israel, Oct. 18, 2021 /PRNewswire/ -- Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, announced today a new peer-reviewed article, with the publication of a chronic migraine study by Pain Reports. The prospective, multi-center, open-label trial (NCT04194008), evaluated the efficacy and safety of remote electrical neuromodulation (REN) for the acute treatment of migraine in chronic migraine patients.

Results from the study's 99 chronic migraine participants demonstrated favorable efficacy of REN, with nearly 60% of the participants experiencing pain relief at 2 hours after the treatment, and nearly 65% of those experiencing sustained pain relief even 24 hours post treatment. Over 20% of the participants experienced disappearance of their headache (pain freedom) at 2 hours post treatment. Additionally, post 2-hour improvement in nausea, photophobia, phonophobia, and functional ability were demonstrated. Only one of the 99 participants (1%) reported a mild, local device-related adverse event which was resolved independently shortly after the treatment.

"Chronic migraine is characterized by headaches experienced on at least 15 days per month," said Brian Grosberg, MD, Director of the Hartford Healthcare Headache Center, who served as the primary investigator of the study. "People with chronic migraine not only have a higher frequency of migraine attacks, but their attacks tend to be more severe than episodic migraine patients. They typically need to take more medications, usually cocktails of preventive and acute medications. The challenge is to relieve the migraine symptoms while avoiding the risk of medication overuse headache (MOH) and other complications. Non-pharmacological interventions such as REN help meet this need by providing a drug-free treatment option. As a clinically validated, non-pharmacological acute treatment option for people with migraine, Nerivio is an excellent fit for fulfilling this need."

"To the best of our knowledge, this was the largest clinical trial of acute treatment of migraine specifically targeting chronic migraine patients," said Liron Rabany, Ph.D., Chief Scientist of Theranica and a co-author of the study paper. "We are determined to continue our clinical development, adding ever-increasing solid evidence of the clinical benefit that REN brings to different sub-populations of people with migraine. All people with migraine, adults or adolescents, should have the option of discussing a non-pharmacological therapy with their healthcare providers, as a first-line treatment option, or as an adjunct."

Worn on the upper arm at the onset of a migraine attack, Nerivio alleviates migraine symptoms without need for medications by utilizing REN to trigger an endogenous analgesic mechanism, known as Conditioned Pain Modulation (CPM). The device is controlled by an app on the patient's smartphone, allowing patients to set the intensity of their treatment.

About Theranica

Theranica is a prescribed digital therapeutics company dedicated to creating effective, safe, affordable, low-side effect therapies for idiopathic pain conditions. The company's award-winning flagship product, Nerivio^®, is the first FDA-cleared smartphone-controlled prescribed wearable device for acute treatment of migraine, and already serves close to 25,000 people with migraine in the USA, including adolescents and veterans. Theranica is expanding its proprietary technology to develop solutions for additional idiopathic pain conditions. Nerivio has received FDA authorization and CE mark for use in acute treatment of episodic and chronic migraine in adult and adolescent patients.

Learn more by visiting our websites, theranica.com, nerivio.com and following us on LinkedIn, Twitter, Instagram and Facebook.

Media Contact:
Nechama Feuerstein
Finn Partners
[email protected]
+1-551-444-0784

Theranica Contacts:

Medical Affairs:
Alit Stark-Inbar, Ph.D.,
[email protected]
+972 54-909-1370

Commercial Affairs:
Ronen Jashek
[email protected] 
+972-72-390-9750

SOURCE Theranica